RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New drug cocktail shows promise for CLL patients
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, umbralisib, and ublituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The study incl…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for Tough-to-Treat blood cancers: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called BGB-11417 in 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. The goal is to see if the drug can shrink or eliminate cancer cells. Particip…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:49 UTC